| アブストラクト | In this study, we aimed to describe the national trends in anti-osteoporosis pharmacotherapy in Japan and assess whether introducing the April 2022 management fee for post hip fracture care was accompanied by changes in pharmacological secondary fracture prevention after hip and vertebral fractures. We conducted a nationwide cross-sectional study using data from the DeSC database. The annual hip and vertebral fracture cohorts included adults aged >/=50 years with an incident fracture without recorded prior anti-osteoporosis prescriptions. In these fracture cohorts, we estimated the proportion of patients who initiated anti-osteoporosis medication within 3 months after fracture, as well as agent-specific initiation proportions. The proportion of patients initiating anti-osteoporosis medication within 3 months of a hip fracture increased starting in 2022, reaching 29.5% in 2023. The corresponding proportion following a vertebral fracture increased slightly, reaching 35.7% in 2023. After hip fracture, the initiation of oral bisphosphonates increased, whereas that of teriparatide declined starting in 2022. In addition, the initiation of other anti-osteoporosis medications declined. After vertebral fracture, the initiation of teriparatide remained stable but that of other anti-osteoporosis medications declined. Initiation of romosozumab following both fractures increased following its market entry. These findings describe changes in post-fracture anti-osteoporosis pharmacotherapy in Japan, including increased treatment initiation after hip fracture, smaller changes after vertebral fracture, and shifts in agent-specific initiation patterns. Further research and longer follow-up are needed to assess whether these patterns are sustained and to clarify their implications for post-fracture osteoporosis care. |
|---|
| ジャーナル名 | Bone |
|---|
| Pubmed追加日 | 2026/6/15 |
|---|
| 投稿者 | Hatano, Masaki; Okada, Akira; Kimura, Yuya; Ishikura, Hisatoshi; Tanaka, Takeyuki; Saito, Taku; Tanaka, Sakae; Yasunaga, Hideo |
|---|
| 組織名 | Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo,;Tokyo, Japan. Electronic address: h-masaki@g.ecc.u-tokyo.ac.jp.;Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate;School of Medicine, The University of Tokyo, Tokyo, Japan.;Department of Health Services Research, Graduate School of Medicine, The;University of Tokyo, Tokyo, Japan.;Tokyo, Japan.;Department of Clinical Epidemiology and Health Economics, School of Public;Health, The University of Tokyo, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42288172/ |
|---|
